950 — Lee's Pharmaceutical Holdings Share Price
0.000.00%
Last trade - 00:00- HK$783.15m
- HK$690.71m
- HK$1.40bn
- 94
- 91
- 89
- 100
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 1.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.56 | ||
| EV to EBITDA | 2.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.13% | ||
| Return on Equity | 5.04% | ||
| Operating Margin | 8.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 1,216.72 | 1,266.16 | 1,233.15 | 1,053.03 | 1,399.97 | 1,461.21 | n/a | 2.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -20.66 | +328.87 | -91.56 | -78.91 | +910.85 | -26.89 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.
Directors
- Siu Fong Lee CHM (64)
- Lin Tom PRE (37)
- Wanee Leelalertsuphakun CMO (61)
- Lit-Fui Lau GMG (52)
- Dingwen Li DHR (55)
- Yueshen Chen OTH (56)
- Zhongyu Jiao OTH (46)
- Tsui Victor OTH (48)
- Guohui Zhang OTH (41)
- Yiu Ming Chow SEC (45)
- Zhongqiang Yang DRC (40)
- Simon Ball NED (40)
- James Gale NED (71)
- Xiaoyi Li NED (58)
- Yau Ching Chan NID (55)
- Yat Cheong Lam NID (54)
- Wah Keung Tsim NID (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 2001
- Public Since
- July 15th, 2002
- No. of Employees
- 993
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 588,835,343
- Address
- Unit 110-111, Bio-Inf. Centre,
- Web
- https://www.leespharm.com/
- Phone
- +852 null23141282
- Auditors
- Confucius International CPA Limited
Upcoming Events for 950
Lee's Pharmaceutical Holdings Ltd Annual Shareholders Meeting
Dividend For 0950.HK - 0.0250 HKD
Half Year 2025 Lee's Pharmaceutical Holdings Ltd Earnings Release
Similar to 950
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Lee's Pharmaceutical Holdings share price?
As of Today at 21:43 UTC, shares in Lee's Pharmaceutical Holdings are trading at HK$1.33. This share price information is delayed by 15 minutes.
How has the Lee's Pharmaceutical Holdings share price performed this year?
Shares in Lee's Pharmaceutical Holdings last closed at HK$1.33 and the price had moved by +22.02% over the past 365 days. In terms of relative price strength the Lee's Pharmaceutical Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +23.41% over the past year.
What are the analyst and broker recommendations for Lee's Pharmaceutical Holdings?
The overall consensus recommendation for Lee's Pharmaceutical Holdings is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lee's Pharmaceutical Holdings dividend yield?
The Lee's Pharmaceutical Holdings dividend yield is 3.38% based on the trailing twelve month period.
Does Lee's Pharmaceutical Holdings pay a dividend?
Last year, Lee's Pharmaceutical Holdings paid a total dividend of HK$0.05, and it currently has a trailing dividend yield of 3.38%.Looking ahead, shares in Lee's Pharmaceutical Holdings are due to go ex-dividend on 2025-05-28 and the next dividend pay date is 2025-06-16.
When does Lee's Pharmaceutical Holdings next pay dividends?
Lee's Pharmaceutical Holdings are due to go ex-dividend on 2025-05-28 and the next dividend pay date is 2025-06-16. The historic dividend yield on Lee's Pharmaceutical Holdings shares is currently 3.38%.
How do I buy Lee's Pharmaceutical Holdings shares?
To buy shares in Lee's Pharmaceutical Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lee's Pharmaceutical Holdings?
As of the previous close price of HK$1.33, shares in Lee's Pharmaceutical Holdings had a market capitalisation of HK$783.15m.
Where are Lee's Pharmaceutical Holdings shares listed?
Here are the trading details for Lee's Pharmaceutical Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 950
What kind of share is Lee's Pharmaceutical Holdings?
Based on an overall assessment of its quality, value and momentum Lee's Pharmaceutical Holdings is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lee's Pharmaceutical Holdings share price forecast for 2025?
The analyst consensus target price for shares in Lee's Pharmaceutical Holdings is HK$1.00. That is 24.81% below the last closing price of HK$1.33.
Analysts covering Lee's Pharmaceutical Holdings currently have a consensus Earnings Per Share (EPS) forecast of HK$0.14 for the next financial year.
Find out moreWhat is the trend in the Lee's Pharmaceutical Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lee's Pharmaceutical Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +14.58%.
As of the last closing price of HK$1.33, shares in Lee's Pharmaceutical Holdings were trading +5.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lee's Pharmaceutical Holdings PE Ratio?
The Lee's Pharmaceutical Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lee's Pharmaceutical Holdings?
Lee's Pharmaceutical Holdings' management team is headed by:
- Siu Fong Lee - CHM
- Lin Tom - PRE
- Wanee Leelalertsuphakun - CMO
- Lit-Fui Lau - GMG
- Dingwen Li - DHR
- Yueshen Chen - OTH
- Zhongyu Jiao - OTH
- Tsui Victor - OTH
- Guohui Zhang - OTH
- Yiu Ming Chow - SEC
- Zhongqiang Yang - DRC
- Simon Ball - NED
- James Gale - NED
- Xiaoyi Li - NED
- Yau Ching Chan - NID
- Yat Cheong Lam - NID
- Wah Keung Tsim - NID